Cannabinol

And then the rest was get a license that didn't exist.

And you can only sell 10 milligram edibles, drinks, CBD, CBD products, whatever, CBN, no synthetics.

And then January came.

And there was no license to be had.

So strain is a commercial and consumer term.

Different strain can have different combination of concentration of the cannabinoids like TSC, CBD, CBG, CBN, et cetera, and terpenes.

But strain names such as OG Kush, Blue Dream, et cetera, are not standardized pharmacological categories.

Yes.

is simply modern applications of AI and how, you know, one of our partners in the distro is always designed around the COA and the source material and how efficiently you can supply that source material to a pharmaceutical application.

So if you think you have a crop and that crop, that plant might have THC, CBN, CBG, all in that plant, CBD in that plant, it might have myrcene, it might have beta-carophyllene, all these different terpenes in it.

Well, Which plant genetics will you grow that give you the best expression of that combination of cannabinoids and terpenes for a particular medical application? So when you start looking at the economic economy of it, you know, 25 years ago, maybe you could only find CBN and trace amounts in a plant somewhere.

So making a CBN based drug would be economically impossible.

Now, 25 years later, people are growing plants trying to express minor cannabinoids, whether that's CBN or THCB or some other minor cannabinoids.

So you've got entire genetic lines now that are optimized for specific pathways and indications.

Now you've got an economic model that's starting to make sense if the input materials are grown at scale and companies like Vantage can extract them efficiently at scale.

Yeah.

So there's been an immense amount of at least small scale research going into isolating these compounds and understanding what different properties they have you know the animal research to understand neurological pathways so while all that science has been catching up the uh technology as well is making it is making it uh you know uh rapidly advance and you know that's something we're really excited about is simply modern applications of AI and how one of our partners in the distro is always designed around the COA and the source material and how efficiently you can supply that source material to a pharmaceutical application.

So if you think you have a crop and the crop, that plant might have THC, CBN, CBG, all in that plant, CBD in that plant, it might have myrcene, it might have beta-carophyllene, all these different terpenes in it.

Well, which plant genetics will you grow that give you the best expression of that the combination of cannabinoids and terpenes for a particular medical application so when you start looking at the economic economy of it you know 25 years ago maybe you could only find cbn and trace amounts in a plant somewhere so making a cbn based drug would be economically impossible Now, 25 years later, people are growing plants trying to express minor cannabinoids, whether that's CBN or THCB or some other minor cannabinoids.

So you've got entire genetic lines now that are optimized for specific pathways and indications.

Now you've got an economic model that's starting to make sense if the input materials are grown at scale and companies like Vantage can extract them efficiently.

Can I give you an example from?

Yeah.

So so we talk about CBN for sleep.

And the interesting thing there is they were the people that always had the federal licence in America, so they grew all the cannabis under licence basically since the 30s at the University of Mississippi.

They've always... been into that and so what they did this new study looked at the stability of plant material extracts oils and isolates of both CBD and THC over prolonged periods of time under different storage environments room temperature refrigeration and freezing let me just take a sip Now, the interesting thing was for THC, exposure to room temperature accelerated the degradation of THC into cannabinole, or CBN.

Storage at negative 20, the freezing, preserved the cannabinoid integrity over extended times, whereas CBD products didn't have that.

They were quite stable at room temperature.